Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer - PubMed
5 hours ago
- #photothermal therapy
- #bladder cancer
- #ferroptosis
- Ferroptosis, a form of regulated cell death, is explored as a novel strategy for bladder cancer therapy.
- A nanoplatform, FBZ@BSA@PDA, combines ferroptosis induction, immunogenic cell death (ICD), and photothermal therapy (PTT) for synergistic treatment.
- Fenbendazole (FBZ) is encapsulated using bovine serum albumin (BSA), and polydopamine (PDA) enhances tissue adhesion and photothermal responsiveness.
- The platform induces lipid peroxidation (LPO), GSH depletion, and mitochondrial dysfunction, leading to tumor cell death via ferroptosis.
- Key ICD markers like calreticulin (CRT), HMGB1, and ATP secretion promote dendritic cell (DC) maturation and T-cell activation.
- FBZ@BSA@PDA shows strong anti-tumor efficacy and biosafety in an orthotopic mouse model of bladder cancer.
- This approach offers a promising localized immune-potentiated therapy for clinical bladder cancer treatment.